TRENTON, N.J. -- (AP) In the latest disappointment over cholesterol pill Vytorin, a major European study in patients with heart valve disease found the drug didn't prevent worsening of the disease or lower the need for valve surgery. Its makers' shares plunged about 15 percent. Full version available to lexis.com subscribers.